{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:11:27Z","timestamp":1790824287437,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025276","name":"Novo Nordisk USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016300","name":"Octapharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.rpth.2025.102719","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:24:50Z","timestamp":1740745490000},"page":"102719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of plasma-derived von Willebrand factor\/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease \u2013 WIL-31 study post hoc analysis"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna V.","family":"Vilchevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adlette","family":"Inati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Djambas Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102719_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.rpth.2025.102719_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211064064","article-title":"Prophylactic management of patients with von Willebrand disease","volume":"12","author":"Franchini","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.102719_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102719_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2020.12.030","article-title":"Translating the success of prophylaxis in haemophilia to von Willebrand disease","volume":"199","author":"Miesbach","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102719_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/hae.14475","article-title":"Social participation is reduced in type 3 von Willebrand disease patients and in patients with a severe bleeding phenotype","volume":"28","author":"Kempers","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib6","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"van Galen","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib7","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.102719_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1160\/TH10-09-0616","article-title":"Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study","volume":"105","author":"Halimeh","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102719_bib9","unstructured":"Octapharma AG. Wilate\u00ae US prescribing information. https:\/\/wilateusa.com\/wp-content\/uploads\/2023\/12\/wilate-full-prescribing-information.pdf; 2023 [accessed March 17, 2025]."},{"key":"10.1016\/j.rpth.2025.102719_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/bloodadvances.2023011742","article-title":"Von Willebrand factor\/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease","volume":"8","author":"Sidonio","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102719_bib11","first-page":"189","article-title":"von Willebrand disease epidemiology, burden of illness and management: a systematic review","volume":"14","author":"Du","year":"2023","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2025.102719_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate\u00ae, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib13","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/hae.12497","article-title":"Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience","volume":"21","author":"Khair","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/hae.12237","article-title":"Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information","volume":"19","author":"Nowak-G\u00f6ttl","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ejh.13778","article-title":"Effectiveness of long-term prophylaxis using pdFVIII\/VWF concentrate in patients with inherited von Willebrand disease","volume":"109","author":"Rugeri","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2025.102719_bib17","first-page":"391","article-title":"A\u00a0phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2025.102719_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/hae.12005","article-title":"Efficacy and safety during formulation switch of a pasteurized VWF\/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease","volume":"19","author":"Castaman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3324\/haematol.11124","article-title":"Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients","volume":"92","author":"Federici","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.102719_bib20","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/jth.14928","article-title":"Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: results from a prospective observational post-marketing study","volume":"18","author":"Goudemand","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102719_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221074348","article-title":"Clinical efficacy and safety of Fanhdi\u00ae, a plasma-derived VWF\/factor VIII concentrate, in von Willebrand disease in Spain: a retrospective study","volume":"28","author":"Jim\u00e9nez-Yuste","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.102719_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.102719_bib24","first-page":"213","article-title":"Pharmacokinetics, efficacy and safety of a plasma-derived VWF\/FVIII concentrate (formulation V) in pediatric patients with von Willebrand disease (SWIFTLY-VWD Study)","volume":"11","author":"Auerswald","year":"2020","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2025.102719_bib25","first-page":"345","article-title":"An open-label extension study to assess the long-term efficacy and safety of a plasma-derived von Willebrand factor (VWF)\/factor VIII (FVIII) concentrate in patients with von Willebrand disease (SWIFT-VWDext Study)","volume":"11","author":"Lissitchkov","year":"2020","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2025.102719_bib26","first-page":"83","article-title":"Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin\u00ae) in paediatric patients under 6 years of age with severe von Willebrand disease","volume":"21","author":"Gouider","year":"2023","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2025.102719_bib27","article-title":"Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report. Hematology.","volume":"28","author":"Berger","year":"2023"},{"key":"10.1016\/j.rpth.2025.102719_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.25656","article-title":"Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease","volume":"95","author":"Abe","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102719_bib29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.24195","article-title":"Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding","volume":"90","author":"Sanders","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102719_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102719_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/2634853521991517","article-title":"Efficacy of Nuwiq\u00ae (Simoctocog Alfa) in patients with hemophilia A who changed and adhered to a pharmacokinetic-guided prophylaxis regimen in the NuPreviq study","volume":"14","author":"Pasi","year":"2021","journal-title":"Clin Med Insights Blood Disord"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:14:33Z","timestamp":1762629273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2475037925000433"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102719","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of plasma-derived von Willebrand factor\/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease \u2013 WIL-31 study post hoc analysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102719"}}